Literature DB >> 2972107

A comparison of the efficacy of four different long-acting boluses to prevent infections with Dictyocaulus viviparus in calves.

F H Borgsteede1, W A de Leeuw, W P vd Burg.   

Abstract

A field study of calves in their first grazing season tested the efficacy of four long-acting devices--a morantel sustained-release bolus, a levamisole sustained-release bolus, an oxfendazole interval bolus, and an albendazole interval bolus--against Dictyocaulus viviparus. The pasture had been previously contaminated by four calves orally inoculated with infective lungworm larvae. The calves were grazed together with four bolus-treated groups, each comprising four calves. Lungworm infection became patent in the experimentally inoculated calves between 22 and 26 days. Infection in the bolus-treated groups became patent after 54 days. The morantel bolus group excreted the most larvae, followed by the albendazole bolus group, and the levamisole bolus group. The oxfendazole bolus group excreted by far the least larvae. Eosinophil curves and ELISA titres showed that treated groups had essentially the same course of infection. The heavy infection to which the treated calves were exposed produced complete immunity in all groups. Challenge infection of 10,000 larvae at housing did not change any of the test parameters. Post-mortem examination showed only one positive calf with few worms. We concluded that when pastures are heavily infested with lungworm larvae, all boluses prevent severe clinical signs and allow build up of solid immunity, although none completely prevent excretion of larvae.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972107     DOI: 10.1080/01652176.1988.9694168

Source DB:  PubMed          Journal:  Vet Q        ISSN: 0165-2176            Impact factor:   3.320


  1 in total

1.  Oxfendazole treatment of non-parasitized lambs and its effect on the immune system.

Authors:  M Stankiewicz; W Cabaj; W E Jonas; L G Moore; W N Chie
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.